Collegium Pharmaceutical’s (COLL) Purchase Rating Repeats at Cantor Fitzgerald

Collegium Pharmaceutical’s (COLL) Purchase Rating Repeats at Cantor Fitzgerald

Cantor Fitzgerald reissued their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report released on Thursday, November 8th. They currently have a $35.00 target price on the specialty pharmaceutical company’s stock.

“. Post 3Q18, we are reiterating our Overweight rating and our 12-month price target of $35. We remain positive on the long-term growth potential of Xtampza, which we expect to be the leading branded extended-release oxycodone over time. We think the company is only in the early stages of building a much-larger portfolio of differentiated opioid and non-opioid pain treatments. Collegium has shown a willingness to work with payers to ensure that the company’s products are available to patients without excessive payer restrictions. Collegium’s lead growth driver is Xtampza, which we continue to believe will replace OxyContin as the largest branded oxycodone ER product.”,” the firm’s analyst commented.

Other research analysts also recently issued reports about the stock. BidaskClub upgraded shares of Collegium Pharmaceutical from a strong sell rating to a sell rating in a research report on Thursday, October 4th. Janney Montgomery Scott set a $27.00 target price on shares of Collegium Pharmaceutical and gave the company a buy rating in a research report on Monday, August 6th. Piper Jaffray Companies set a $34.00 target price on shares of Collegium Pharmaceutical and gave the company a buy rating in a research report on Wednesday, July 11th. HC Wainwright restated a buy rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. Finally, Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Tuesday, October 23rd. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Collegium Pharmaceutical currently has an average rating of Buy and an average price target of $31.71.

NASDAQ COLL traded up $0.21 on Thursday, reaching $19.19. 265,465 shares of the company’s stock traded hands, compared to its average volume of 498,532. The company has a market capitalization of $638.01 million, a PE ratio of -7.77 and a beta of 0.24. Collegium Pharmaceutical has a fifty-two week low of $13.70 and a fifty-two week high of $29.90. The company has a debt-to-equity ratio of 4.17, a current ratio of 0.78 and a quick ratio of 0.75.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). The business had revenue of $70.20 million for the quarter, compared to analyst estimates of $74.79 million. Collegium Pharmaceutical had a negative net margin of 30.13% and a negative return on equity of 70.06%. The company’s revenue for the quarter was up 485.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.45) earnings per share. Research analysts expect that Collegium Pharmaceutical will post -1.8 earnings per share for the current year.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the company’s stock in a transaction dated Thursday, November 15th. The shares were sold at an average price of $16.60, for a total value of $415,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 25.76% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its stake in Collegium Pharmaceutical by 9.4% during the 1st quarter. Royal Bank of Canada now owns 28,238 shares of the specialty pharmaceutical company’s stock valued at $721,000 after acquiring an additional 2,437 shares in the last quarter. Rhumbline Advisers grew its stake in Collegium Pharmaceutical by 11.5% during the 2nd quarter. Rhumbline Advisers now owns 28,341 shares of the specialty pharmaceutical company’s stock valued at $676,000 after acquiring an additional 2,916 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in Collegium Pharmaceutical by 34.7% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 13,704 shares of the specialty pharmaceutical company’s stock valued at $327,000 after acquiring an additional 3,530 shares in the last quarter. Strs Ohio grew its stake in Collegium Pharmaceutical by 13.2% during the 2nd quarter. Strs Ohio now owns 33,500 shares of the specialty pharmaceutical company’s stock valued at $798,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Teachers Advisors LLC grew its stake in Collegium Pharmaceutical by 6.2% during the 3rd quarter. Teachers Advisors LLC now owns 77,036 shares of the specialty pharmaceutical company’s stock valued at $1,136,000 after acquiring an additional 4,484 shares in the last quarter. Hedge funds and other institutional investors own 96.90% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Story: Fundamental Analysis

Related posts

Leave a Comment